share_log

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/09/24 16:51

Moomoo AI 已提取核心信息

BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.
BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.
BioVie公司，一家总部位于内华达州的生物制药公司，在2024年9月24日向证券交易委员会（SEC）提交了一份修订后的8-K/A表格。这次修订涉及公司已经提交的报告，报告内容涉及与ThinkEquity LLC签订的放置代理协议。该协议涉及以每股1.53美元的价格发行和销售多达1,960,800股BioVie的A类普通股，以及每张权证定价为1.5299美元的预先拟定权证，以及用于购买相等数量股票的普通股购买权证。修订旨在包括一份修订后的附件5.1，其中包括Fennemore Craig, P.C.的法律意见。原8-K表格没有进行其他修改。修订的附件包括预先拟定和普通权证的形式、放置代理的权证协议、法律意见以及法律公司的同意书，以及2024年9月23日的新闻稿。
BioVie公司，一家总部位于内华达州的生物制药公司，在2024年9月24日向证券交易委员会（SEC）提交了一份修订后的8-K/A表格。这次修订涉及公司已经提交的报告，报告内容涉及与ThinkEquity LLC签订的放置代理协议。该协议涉及以每股1.53美元的价格发行和销售多达1,960,800股BioVie的A类普通股，以及每张权证定价为1.5299美元的预先拟定权证，以及用于购买相等数量股票的普通股购买权证。修订旨在包括一份修订后的附件5.1，其中包括Fennemore Craig, P.C.的法律意见。原8-K表格没有进行其他修改。修订的附件包括预先拟定和普通权证的形式、放置代理的权证协议、法律意见以及法律公司的同意书，以及2024年9月23日的新闻稿。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间